Kuronishi Megumi, Ozawa Yoichi, Kimura Takayuki, Li Shuyu Dan, Kato Yu
Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba, Japan.
Eisai Inc., Nutley, New Jersey.
Cancer Res Commun. 2025 Mar 1;5(3):398-408. doi: 10.1158/2767-9764.CRC-24-0403.
A novel gene signature for MVD was developed. This MVD gene score enables the estimation of MVD, reflecting the sensitivity to antiangiogenic inhibitors, in transcriptomic datasets. We demonstrated the utility of the MVD gene score together with a T cell-inflamed gene signature for potential future use as a clinical biomarker.
开发了一种用于微血管密度(MVD)的新型基因特征。这种MVD基因评分能够在转录组数据集中估计MVD,反映对抗血管生成抑制剂的敏感性。我们证明了MVD基因评分与T细胞炎症基因特征一起作为潜在临床生物标志物的未来用途。